Hyperuricaemia Treatment Composition with Serine and NAC
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hyperuricaemia, gout, and renal impairment are suboptimal, with many patients not receiving adequate urate-lowering therapy and experiencing impaired renal function, and existing substances like glycine, tryptophan, L-carnitine, and nicotinamide mononucleotide combinations show limited efficacy.
Innovation Solution
A composition comprising serine, N-acetyl cysteine, carnitine, and nicotinamide riboside, with specific molar ratios and dosages, is administered to lower serum uric acid and creatinine levels, indicating improved kidney health.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing substances like glycine, tryptophan, L-carnitine, and nicotinamide mononucleotide are used for treatment, then some urate-lowering effect is achieved, but the efficacy is limited and renal function remains impaired
Solution Approach 1:
The patent combines five specific substances (serine, N-acetyl cysteine, L-carnitine, nicotinamide riboside, and zinc) into a unified composition with optimized molar ratios. This merging of multiple substances with complementary mechanisms addresses the limitations of single-substance or previous combination therapies, achieving both superior urate-lowering efficacy and renal protection
Solution Approach 2:
The invention creates a composite therapeutic composition where each substance contributes specific properties: serine for uric acid metabolism, N-acetyl cysteine for antioxidant and renal protection, L-carnitine for metabolic regulation, nicotinamide riboside for cellular energy and kidney function, and zinc for enzymatic support. The synergistic interaction of these components produces therapeutic effects greater than the sum of individual substances
2Reliability
If higher doses of individual substances are administered to improve efficacy, then treatment effectiveness increases, but the complexity of dosing and treatment protocol increases
Solution Approach 1:
By merging all five substances into a single pre-formulated composition with predetermined optimal molar ratios, the patent eliminates the need for complex multi-substance dosing regimens. Patients simply administer one composition, which internally maintains the precise stoichiometric relationships needed for maximum efficacy, thereby reducing dosing complexity while preserving treatment effectiveness
Data Source
Figure 1(A)~1(B)
Figure 2(A)~2(B)
Figure 3A~3B
AI summary
A composition for use in a therapeutic method of treatment or prevention of hyperuricaemia, gout and/or renal impairment, said composition comprising: A) serine, glycine, betaine, N-acetylglycine, N-acetylserine, dimethylglycine, sarcosine and/or phosphoserine; B) N-acetyl cysteine, cysteine and/or cystine; C) optionally carnitine, deoxycarnitine, gamma-butyrobetaine, 4- trimethylammoniobutanal, 3-hydroxy-N 6,N6,N6-trimethyl-L-lysine, N6,N6,N6- trimethyl-L-lysine and/or lysine; and D) nicotinamide riboside, quinolinate, deamino-NAD+, nicotinate D-ribonucleotide, nicotinamide D-ribonucleotide, nicotinate D-ribonucleoside, nicotinamide and/ or nicotinate.